Patents by Inventor James F Holland
James F Holland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8664272Abstract: Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 30, 2006Date of Patent: March 4, 2014Assignees: Temple University—Of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount SinaiInventors: E. Premkumar Reddy, M. V. Ramana Reddy, James F. Holland, Lewis R. Silverman, Svetlana Zinzar
-
Patent number: 8106033Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 10, 2006Date of Patent: January 31, 2012Assignees: Temple University - Of The Commonwealth System of Higher Education, Mount Sinai School of MedicineInventors: E. Premkumar Reddy, James F. Holland
-
Publication number: 20100305059Abstract: Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 30, 2006Publication date: December 2, 2010Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: E. Premkumar Reddy, M.V. Ramana Reddy, James F. Holland, Lewis R. Silverman, Svetlana Zinzar
-
Patent number: 7510707Abstract: The present invention relates to a gene selectively expressed in malignant cells and associated with the development of androgen resistance in prostate cancer. Levels of the gene, termed “PAR” (for Prostate Androgen Regulated), its RNA transcript, and its protein product are all present at increased levels in malignant cells, such as breast cancer and prostate cancer cells. The present invention provides for PAR nucleic acid molecules and proteins, for antibodies that specifically bind to PAR proteins, and to methods for diagnosing and treating cancers that utilize such molecules.Type: GrantFiled: June 24, 2002Date of Patent: March 31, 2009Assignee: New York University Mt. Sinai School of MedicineInventors: Micsunica Platica, Ovidu Platica, James F. Holland
-
Publication number: 20080161252Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 10, 2006Publication date: July 3, 2008Applicants: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: E. Premkumar Reddy, James F. Holland
-
Aminobenzoic acid derivatives having anti-tumorigenic activity, methods of making and using the same
Patent number: 6590123Abstract: The present invention provides for haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurea, 3-bromoacetoamido, benzoylurea, 3-iodoacetoamido, benzoylurea, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with methods of making and using the derivatives, are also provided.Type: GrantFiled: August 29, 2001Date of Patent: July 8, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventors: George J Bekesi, Jian-Dong Jiang, Imre Weisz, John Roboz, James F Holland -
Publication number: 20030005471Abstract: The present invention relates to a gene selectively expressed in malignant cells and associated with the development of androgen resistance in prostate cancer. Levels of the gene, termed “PAR” (for Prostate Androgen Regulated), its RNA transcript, and its protein product are all present at increased levels in malignant cells, such as breast cancer and prostate cancer cells. The present invention provides for PAR nucleic acid molecules and proteins, for antibodies that specifically bind to PAR proteins, and to methods for diagnosing and treating cancers that utilize such molecules.Type: ApplicationFiled: June 24, 2002Publication date: January 2, 2003Inventors: Micsunica Platica, Ovidu Platica, James F. Holland
-
Aminobenzoic acid derivatives having anti-tumorigenic activity, methods of making and using the same
Publication number: 20020022747Abstract: Haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurea, 3-bromoacetoamido, benzoylurea, 3-iodoacetoamido, benzoylurea, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with method of making and using the derivatives, are also provided.Type: ApplicationFiled: August 29, 2001Publication date: February 21, 2002Inventors: George J. Bekesi, Jian-Dong Jiang, Imre Weisz, John Roboz, James F. Holland -
Patent number: 6294695Abstract: Haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity are inclosed. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurca, 3-bromoacctoamido, benzoylurea, 3-todoacetoamido, benzoylurca, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with method of making and using the derivatives, are also provided.Type: GrantFiled: February 26, 1999Date of Patent: September 25, 2001Assignee: Mount Sinai School of Medicine of the City University of New YorkInventors: George J Bekesi, Jian-Dong Jiang, Imre Weisz, John Roboz, James F Holland
-
Patent number: 5888817Abstract: The present invention is directed to pituitary differentiation factor (PDF), a pituitary factor that is capable of differentiating cells including breast cancer and prostatic cancer cells. Isolated nucleic acids encoding PDF and related vectors and host cells are also provided. Restoration of differentiating ability to malignantly transformed cells provides a modality of cancer therapy. The isolated and purified PDF of the invention is accordingly useful in the treatment of breast and prostatic cancer.Type: GrantFiled: November 25, 1997Date of Patent: March 30, 1999Assignee: The Mount Sinai School of MedicineInventors: Micsunica Platica, Ovidiu Platica, James F. Holland
-
Patent number: 5795740Abstract: The present invention is directed to pituitary differentiation factor (PDF), a pituitary factor that is capable of differentiating cells including breast cancer and prostatic cancer cells. Isolated nucleic acids encoding PDF and related vectors and host cells are also provided. Restoration of differentiating ability to malignantly transformed cells provides a modality of cancer therapy. The isolated and purified PDF of the invention is accordingly useful in the treatment of breast and prostatic cancer.Type: GrantFiled: July 9, 1997Date of Patent: August 18, 1998Assignee: Mount Sinai School of MedicineInventors: Micsunica Platica, Ovidiu Platica, James F. Holland
-
Patent number: 4666834Abstract: A new technique is disclosed for assaying for the presence of invasive cancer. While based on leukocyte adherence inhibition, it is improved by using relatively long lived radio-labeled leukocytes, fractionation of the leukocytes to separately treat T-cells and monocytes and by providing for human plasma or serum in the incubation medium.Type: GrantFiled: March 28, 1984Date of Patent: May 19, 1987Assignee: Mount Sinai School of Medicine of the City University of New YorkInventors: Julius G. Bekesi, James F. Holland, Peter H. Tsang
-
Patent number: 4553869Abstract: A mechanical torque transmitting apparatus such as a one-way clutch which includes two distinct sets of flexural arms (primary and auxiliary) and a cylindrical engagement surface. The primary flexural arm is adapted to be in edgewise continuous engagement with the cylindrical surface. Preferably, the primary flexural arm has a long, straight, narrow cross-section area and applies a relatively low force against the cylindrical surface when said surface is rotating in a free-wheeling direction. In the non free-wheeling direction, the force against the cylindrical surface increases until the rotational forces overcome and buckle the primary flexural arm whereupon the auxiliary flexural arm is brought into contact with the cylindrical surface to resist further rotation.Type: GrantFiled: September 12, 1983Date of Patent: November 19, 1985Assignee: International Business Machines Corp.Inventors: Douglas E. Alexander, James F. Holland, Herbert G. Leonard, Alvin R. Reed
-
Patent number: 4455379Abstract: A new technique is disclosed for assaying for the presence of invasive cancer. While based on leukocyte adherence inhibition, it is improved by using relatively long lived radio-labeled leukocytes, fractionation of the leukocytes to separately treat T-cells and monocytes and by providing for human plasma or serum in the incubation medium.Type: GrantFiled: July 21, 1981Date of Patent: June 19, 1984Assignee: Mount Sinai School of Medicine of the City University of New YorkInventors: Julius G. Bekesi, James F. Holland, Peter H. Tsang